JPMorgan Chase & Co. lifted its position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 10.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,854,334 shares of the medical research company’s stock after purchasing an additional 1,225,420 shares during the period. JPMorgan Chase & Co. owned about 0.09% of Natera worth $2,944,800,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Integrated Wealth Concepts LLC lifted its position in Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares during the last quarter. NewEdge Advisors LLC lifted its position in Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,847 shares during the last quarter. Focus Partners Wealth lifted its position in Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in Natera in the second quarter valued at $298,000. Finally, WINTON GROUP Ltd purchased a new stake in Natera in the second quarter valued at $558,000. 99.90% of the stock is owned by hedge funds and other institutional investors.
Natera Stock Performance
NASDAQ NTRA opened at $215.31 on Monday. The firm has a market cap of $30.83 billion, a PE ratio of -132.09 and a beta of 1.56. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36. The firm’s fifty day moving average is $204.19 and its two-hundred day moving average is $216.13.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on Natera
Insider Buying and Selling at Natera
In other Natera news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director directly owned 1,076,198 shares in the company, valued at approximately $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the transaction, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 156,530 shares of company stock valued at $33,914,062. Company insiders own 5.05% of the company’s stock.
Natera Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
